Although caution should also be taken in comparing our study with those of other FGFR inhibitors, tumor response to pemigatinib in our study was numerically better than that with infigratinib (ORR, 18.8%; DCR, 83.3%),33 derazantinib (ORR, 20.7%; DCR, 82.8%),34 and TAS‐120 (ORR, 25%; DCR, 79%)35 for cholangiocarcinoma carrying FGFR2 fusions or rearrangements in predominantly white populations. This evidence concerns the gene FGFR2 and neoplasm.